跳至主要内容
临床试验/CTIS2022-501649-54-01
CTIS2022-501649-54-01进行中(未招募)1 期

Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trial - The ‘DREAM’ trial

Gentofte Hospital0 个研究点目标入组 54 人开始时间: 2022年11月17日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • Age 18–75 years, BMI = 30 kg/m², History of at least one attempt to lose body weight

排除标准

  • A self-reported change in body weight = 5% within the last 90 days prior to the screening visit, Treatment with any therapy, including endoscopic procedures and/or medication (e.g. liraglutide, bupropion/naltrexone and orlistat), intended for weight management within 90 days prior to screening, Previous, current, or planned (during the trial period) obesity treatment with surgery or a weight loss device < 1 year prior to screening, Glycated haemoglobin (HbA1c) = 48 mmol/mol, History of type 1 diabetes or type 2 diabetes

研究者

相似试验